Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

L. Paz-Ares, A. Spira, D. Raben, D. Planchard, B. C. Cho, M. Özgüroğlu, D. Daniel, A. Villegas, D. Vicente, R. Hui, S. Murakami, D. Spigel, S. Senan, C. J. Langer, B. A. Perez, A. M. Boothman, H. Broadhurst, C. Wadsworth, P. A. Dennis, S. J. AntoniaC. Faivre-Finn

Research output: Contribution to journalArticlepeer-review

105 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science